{"preliminary_commentary":{"by_channel":{"podcast":28,"youtube":27,"x_thread":11},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03884101\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-21T14:50:56.704Z","note":"Automated from the 40 newest of 66 indexed sources (Apr 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether patients with prior (neo)adjuvant platinum gain more from lenvatinib-pembrolizumab than from carboplatin-paclitaxel\n- Whether carboplatin-paclitaxel alone remains a relevant control arm now that chemotherapy plus immunotherapy is standard\n- Whether the dMMR subgroup supports dropping chemotherapy from first-line immunotherapy-based treatment","kind":"questions"},"drugs_tested":[["lenvatinib","pembrolizumab"]],"indication":"first-line advanced or recurrent endometrial cancer","name":"LEAP-001","nct_id":"NCT03884101","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=leap-001-nct03884101. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"LEAP-001","arms":[{"description":"Participants receive lenvatinib daily and pembrolizumab once at the start of each 3-week treatment cycle.","label":"Lenvatinib + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants receive paclitaxel and carboplatin once at the start of each 3-week treatment cycle.","label":"Paclitaxel + Carboplatin","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eisai Inc."],"completion_date":{"date":"2025-02-05","type":"ACTUAL"},"conditions":["Endometrial Neoplasms"],"enrollment":{"count":842,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Lenvatinib","otherNames":["E7080, MK-7902, LENVIMA®"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["MK-3475, KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Paclitaxel","otherNames":["TAXOL®, ONXAL®"],"type":"DRUG"},{"name":"Carboplatin","otherNames":["PARAPLATIN®"],"type":"DRUG"}],"last_update":"2026-02-02","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-10-02","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Mismatch Repair Proficient (pMMR) Participants","timeFrame":"Up to approximately 44 months"},{"measure":"PFS Based on RECIST 1.1 as Assessed by BICR in All Randomized Participants","timeFrame":"Up to approximately 44 months"},{"measure":"Overall Survival (OS) in pMMR Participants","timeFrame":"Up to approximately 51 months"},{"measure":"OS in All Randomized Participants","timeFrame":"Up to approximately 51 months"}],"references":[{"citation":"Marth C, Moore RG, Bidzinski M, Pignata S, Ayhan A, Rubio MJ, Beiner M, Hall M, Vulsteke C, Braicu EI, Sonoda K, Wu X, Frentzas S, Mattar A, Lheureux S, Chen X, Hasegawa K, Magallanes-Maciel M, Choi CH, Shalkova M, Kaen D, Wang PH, Berger R, Okpara CE, McKenzie J, Yao L, Orlowski R, Khemka V, Gilbert L, Makker V; ENGOT-en9/LEAP-001 Investigators. First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial. J Clin Oncol. 2025 Mar 20;43(9):1083-1100. doi: 10.1200/JCO-24-01326. Epub 2024 Nov 26.","pmid":"39591551","type":"RESULT"},{"citation":"Marth C, Lorusso D, Bidzinski M, Scollo P, Vardar MA, Oaknin A, Kaen DL, Nogueira-Rodrigues A, Miller DS, Hasegawa K, MacKay H, Moore RG, Santin AD, Yunokawa M, Romero I, Pignata S, Baron-Hay S, Kim YM, Amit A, Ghamande S, Danska-Bidzinska A, Tarnawski R, Wang PH, Yu Z, Slomovitz BM, Okpara CE, McKenzie J, Meng R, Orlowski R, Makker V. Lenvatinib plus pembrolizumab in participants with advanced or recurrent endometrial cancer: Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. Int J Gynecol Cancer. 2026 Jul;36(7):104693. doi: 10.1016/j.ijgc.2026.104693. Epub 2026 Apr 12.","pmid":"42167105","type":"DERIVED"},{"citation":"Marth C, Moore RG, Bidzinski M, Salutari V, Altundag O, Rubio MJ, Levy T, Stillie A, Vulsteke C, Witteler R, Ariyoshi K, Wu X, Frentzas S, Mattar A, Slomovitz BM, Lheureux S, Chen X, Hasegawa K, Magallanes M, Choi CH, Shalkova M, Kaen DL, Cadoo K, Yao L, McKenzie J, Okpara CE, Meng R, Orlowski R, Gilbert L, Makker V. First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: 1-Year follow-up after final analysis of the ENGOT-en9/LEAP-001 phase 3 trial. Int J Gynecol Cancer. 2026 Jan;36(1):102795. doi: 10.1016/j.ijgc.2025.102795. Epub 2025 Nov 11.","pmid":"41494216","type":"DERIVED"},{"citation":"Marth C, Tarnawski R, Tyulyandina A, Pignata S, Gilbert L, Kaen D, Rubio MJ, Frentzas S, Beiner M, Magallanes-Maciel M, Farrelly L, Choi CH, Berger R, Lee C, Vulsteke C, Hasegawa K, Braicu EI, Wu X, McKenzie J, Lee JJ, Makker V. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Int J Gynecol Cancer. 2022 Jan;32(1):93-100. doi: 10.1136/ijgc-2021-003017. Epub 2021 Nov 19.","pmid":"34799418","type":"DERIVED"}],"start_date":{"date":"2019-04-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)","url":"https://clinicaltrials.gov/study/NCT03884101"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/leap-001-nct03884101"}